Navigation Links
Newer Blood Test Predicts Diabetes, Heart Disease
Date:3/3/2010

A1C outperforms fasting glucose in predicting heart disease and stroke risk, study finds,,,,

WEDNESDAY, March 3 (HealthDay News) -- The newer hemoglobin A1C test predicts diabetes as well as the traditional fasting blood sugar test, but it beats that old standard in predicting a patient's future risk of heart disease and stroke, new research shows.

After adjusting for common cardiovascular disease risk factors, the study found that while A1C levels high enough to diagnose diabetes were associated with nearly twice the risk of coronary heart disease, no such association was found with fasting glucose readings high enough to trigger a diabetes diagnosis.

The A1C test is also known as a glycated hemoglobin test, and using a small blood sample, it measures your average blood sugar levels for the past two to three months.

"Our data show that glycated hemoglobin is a really potent risk factor for diabetes and cardiovascular disease. If you have abnormal glycated hemoglobin results, you should be targeted for diabetes and cardiovascular disease interventions," said the study's lead author, Elizabeth Selvin, an assistant professor of epidemiology and medicine in the department of epidemiology at the Johns Hopkins Bloomberg School of Public Health in Baltimore.

In January, the American Diabetes Association (ADA) recommended that doctors could begin using the A1C test for diagnosis of diabetes. Previously, the test wasn't recommended because it hadn't been standardized from lab to lab. The ADA set the level for diagnosis of diabetes at 6.5 percent or higher, and the diagnosis of pre-diabetes for levels of 5.7 to 6.4 percent.

The A1C percentage is the amount of a person's hemoglobin that is glycated or glycosylated.

For the current study, Selvin and her colleagues measured A1C from more than 11,000 stored blood samples from the Atherosclerosis Risk in Communities Study, which began in 1990. None of the study volunteers had diabetes or cardiovascular disease at the time the blood samples were taken.

The researchers then compared the A1C levels to fasting blood sugar levels and to the 15 years of overall health follow-up information gathered for the previous study.

During that time, 2,251 people were diagnosed with diabetes, nearly 1,200 were diagnosed with heart disease and 358 people had an ischemic (non-bleeding) stroke, according to the study.

As expected, the researchers found that elevated A1C levels were associated with an increased risk of being diagnosed with diabetes. Those with an A1C of less than 5 percent had a 48 percent reduced risk of diabetes, while people whose A1Cs were between 5 and 5.5 percent had a normal risk of diabetes. From there, however, the risk quickly went up. Those with an A1C of 5.5 to 6 percent had an 86 percent increased risk of diabetes. For those between 6 and 6.5 percent, the risk more than quadrupled. For people with levels above 6.5 percent, the odds of being diagnosed were more than 16 times higher than for someone with levels under 5.5 percent. These results were similar to those for fasting glucose levels, the study authors noted.

Where fasting glucose and A1C differed greatly, however, was in the prediction of future heart disease and stroke risk. While fasting glucose failed to predict future risk, the study found that A1C levels accurately did so.

People with A1Cs under 5.5 percent had an average risk of heart disease and stroke, but for people with an A1C between 5.5 and 6 percent, the risk went up 23 percent. For those with an A1C between 6 and 6.5 percent, the risk of cardiovascular disease jumped to 78 percent. When A1C went over 6.5 percent, the risk of cardiovascular disease went up nearly twofold.

Results of the study are published in the March 4 issue of the New England Journal of Medicine.

"This is a test that's been around for a long time, and the old dictum was that it couldn't be used to predict cardiovascular disease," said Dr. Rafael Gonzalez, director of cardiology at Scott & White Healthcare in Round Rock, Texas. "But this study shows it may be a great marker -- the higher the A1C, the greater the risk. This tells us we may need to be more aggressive with prevention in people with higher levels, maybe push for lower LDL (bad) cholesterol, emphasize lifestyle factors," he explained.

"Diabetes is like high blood pressure -- the consequences don't come right away. And, sometimes that makes people think, 'Why do I need to be on this medicine?' So, this is further evidence, and may be a good way to get people's attention," Gonzalez added.

More information

Learn more about the A1C test from the U.S. National Library of Medicine.



SOURCES: Elizabeth Selvin, Ph.D., M.P.H., assistant professor, epidemiology and medicine, department of epidemiology, Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore; Rafael Gonzalez, M.D., director, cardiology, Scott & White Healthcare, Round Rock, Texas; March 4, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Newer cornea transplant surgery shows short- and long-term promise
2. Newer Drug More Effective in Psoriasis Treatment
3. Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan
4. Newer Blood Thinners May Outperform Old Standbys
5. Newer heart devices significantly improve survival, complication rate and quality of life
6. Newer, Better Tests for Heart Attacks
7. Newer Drug Beats Tamoxifen for Older Breast Cancer Patients
8. The Other Cruciate Ligament: Newer Treatments for PCL Tears
9. Newer Blood Tests May Not Improve Heart Risk Assessment
10. FDA Panel OKs Newer Antipsychotics for Children
11. FDA Panel Mulls Newer Antipsychotics for Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: